Adcetris.docx

Adcetris Manufacturer and the year introduced to the global market: The manufacturer: Takeda Pharmaceutical Company, Osaka, Japan The year introduced to the global market: 2022 Composition and nature of Adcetris: Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) a type of bioph...

Adcetris Manufacturer and the year introduced to the global market: The manufacturer: Takeda Pharmaceutical Company, Osaka, Japan The year introduced to the global market: 2022 Composition and nature of Adcetris: Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) a type of biopharmaceutical that combines the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy. Indication: Adcetris (brentuximab vedotin) is indicated for the treatment of: Classical Hodgkin lymphoma (HL) Systemic anaplastic large cell lymphoma (sALCL) Side effects: Peripheral Neuropathy: Tingling, numbness, or pain in the extremities. Neutropenia: Low levels of neutrophils, a type of white blood cell. Storage: Store the sealed vial in a refrigerator within the temperature range of 2-8 degrees Celsius, ensuring that freezing is avoided. Maintain the vial in its original container to shield it from light exposure. Store the medication in a location inaccessible to children. Conventional drugs are used for the same purpose: Bleomycin Vinblastine